PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1372016
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1372016
According to Stratistics MRC, the Global Glycomics Market is accounted for $2.13 billion in 2023 and is expected to reach $6.61 billion by 2030 growing at a CAGR of 17.5% during the forecast period. Glycomics is a field of study within molecular biology and biochemistry that focuses on the comprehensive analysis of the structure, function, and biology of carbohydrates (sugars) in biological systems. It involves the study of complex carbohydrates, also known as glycans, and their interactions with other molecules in cells and organisms. Its research has far-reaching implications for understanding of biological processes, disease mechanisms, and the development of novel therapies.
According to a study published in February 2022 by researchers at the University of Copenhagen's Center for Glycomics, Heparin can now be produced without using animals through glycomics studies.
Growing research in glycomics reveals the critical role of glycans in various biological processes, diseases, and therapeutic development. This broadening scope creates a wider market for glycomics technologies across biomedicine applications. Increased research in glycomics fosters innovation in analytical techniques. With increased research, there is a demand for more accessible and cost-effective glycomics technologies. It also creates a strong demand for specialized tools, technologies, and services. These aspects are propelling the market growth.
Glycans are highly diverse and structurally complex molecules. Standardizing the analysis and characterization of glycans across different research settings and laboratories can be challenging, leading to potential inconsistencies and difficulties in data interpretation. In addition, its limited commercial standards, varied analytical techniques, environmental factors, structural diversity and evolutionary variabilites hinder the market demand.
Glycomics research plays a crucial role in identifying specific glycan structures associated with various types of cancer. Understanding these unique glycan patterns allows for the development of accurate and reliable cancer biomarkers. It improves precision in cancer subtyping. Also, glycomics research may lead to the discovery of multiple glycan biomarkers associated with a specific cancer type. Combining these markers into a panel can further enhance diagnostic accuracy. Further, its practical implications for improving cancer detection, treatment, and patient outcomes are accelerating the market growth.
Research labs, particularly those with limited budgets or in academic settings, may face challenges in acquiring and maintaining the necessary glycomics equipment and reagents. This can lead to a slower pace of research or even deter some labs from entering the field. The high cost of instruments and reagents may deter companies and manufacturers from investing in research and development for glycomics technologies. Therefore, the high cost of entry can potentially slow down the growth of the glycomics market.
The COVID-19 pandemic had both direct and indirect impacts on the field of Glycomics. Many research laboratories and institutions faced disruptions in their operations due to lockdowns, restrictions, and safety measures. The financial impact of the pandemic had a long-term effect on research funding. On the positive side, the pandemic highlighted the importance of understanding the role of glycans in viral infections. Researchers have explored the potential of glycans in the development of therapeutics, vaccines, or diagnostics related to COVID-19.
The kits segment is estimated to have a lucrative growth. Glycomics kits are specialized sets of reagents, tools, and protocols designed to facilitate the analysis and study of complex carbohydrates (glycans) in biological samples. They provide a standardized set of reagents and methods for the comprehensive profiling of glycans in biological samples. Glycomics kits include enzymes, labeling agents, and other tools necessary for the enzymatic release and modification of glycans, enabling detailed structural analysis. They play a crucial role in the diagnostics and quality control in biopharmaceuticals.
The drug discovery & development segment is anticipated to witness the highest CAGR growth during the forecast period. The integration of glycomics into drug discovery and development processes leads to more precise and effective therapies, ultimately benefiting patients by improving treatment outcomes and minimizing side effects. Glycomics can contribute to the design of drugs with reduced off-target effects and improved selectivity. It can also improve vaccine efficiency. All these factors are driving the segment growth.
North America is projected to hold the largest market share during the forecast period. North America, comprising the United States and Canada, represented one of the largest glycomics markets globally. North America is home to numerous prominent research institutions, universities, and academic medical centers. The region's advanced healthcare infrastructure, robust research ecosystem, and significant investments in biotechnology and life sciences contributed to the market's size and growth.
Asia Pacific is projected to have the highest CAGR over the forecast period. The Glycomics market in Asia Pacific includes a mix of global biotechnology companies, academic research institutions, and local manufacturers. Both established players and emerging start-ups contribute to the competitive landscape. The biopharmaceutical industry in Asia Pacific is expanding rapidly. The shift towards personalized medicine in the healthcare industry drives the demand for glycomics technologies in this region.
Some of the key players profiled in the Glycomics Market include: Asparia Glycomics, Merck KGaA, Bruker, Thermo Fisher Scientific, Inc, New England Biolabs, Waters Corporation, Takara Bio Inc, Agilent Technologies Inc., RayBiotech Life, Inc., Shimadzu Corporation, Danaher, Lectenz Bio, Intellihep Limited, Sanofi Corporation and Bayer AG.
In August 2023, Thermo Fisher Scientific the world leader in serving science, announced the commercial launch of the EXENT® Solution, after receiving IVDR certification*. The EXENT solution is a fully integrated and automated mass spectrometry system designed to transform diagnosis and assessment for patients with monoclonal gammopathies.
In June 2022, Sanofi announced the launch of its first Digital Accelerator to foster its ambition to become a leading digital healthcare company. The Accelerator will develop products and solutions that will support Sanofi's mission to transform the practice of medicine with the use of digital, data and artificial intelligence (AI).
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.